

## **Information about proposed Board of Directors Annual General Meeting 2012**

---

### *Proposal for re-election of the current members of the board of directors:*

#### **Adine Grate Axén**

Born 1961. MBA from Stockholm School of Economics, Harvard AMP. Board member since 2010. Chairman of Nasdaq OMX Stockholm's Listing Committee and Alhanko & Johnson AB. Advisor and working board member of Hi3GS Holding AB. Board member of Sampo OY, 3G Infrastructure Services AB, vice Chairman Sjunde AP-Fonden, Adine Grate AB and Swedavia AB. Previous Member of the Commission for the sale of shares in companies with state ownership, board member of Gambro AB and OMX AB. 1994–2007, various senior management positions and board assignments within Investor AB and member of the management group 1999–2007. Board member of Acne Studios Holding AB, EDB Ergo Group AS, Micaro AB, and Carnegie Investment Bank AB.

Shares: 32 000

Independent in relation to the company and its management and in relation to the company's principal shareholders.

#### **Bo Jesper Hansen**

Born 1958. MD and Ph.D. from Copenhagen University. Board member since 2010, Chairman since 2010. Board member of MipSalus, TopoTarget A/S, ZymenexA/S, Gambro AB, Hyperion Therapeutics Inc., Genspera Inc, Orphazyme ApS and CMC Kontrast AB. Has previously held various positions in Swedish Orphan International AB since 1993, CEO 1998 – 2010. Medical advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi. Founder of ScandinavianMedical Research.

Shares: 8 893 846

Dependent in relation to the company and its management but independent in relation to the company's principal shareholders.

#### **Lennart Johansson**

Born 1955. MBA from Stockholm School of Economics. Board member since 2010. Member of the management team and Head of the Financial Investments group at Investor AB. Board member of Hi3G and Lindorff group. Previously CEO in b-business partners and Emerging Technologies AB. Board member of SAAB AB, Acti AB, Synchron International AB, IBX Group AB, Gambro Holding AB, Gambro Hospital AB, Management Participation Programme (MPP) BCTAB and Mölnlycke Group. Chairman of Invifed AB with subsidiaries and Cator Holding AB. Board member of

Shares: 20 000

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

**Helena Saxon**

Born 1970. MBA from Stockholm School of Economics. Board member since 2011. Investment Manager at Investor AB, board member of Gambro AB. Previously CFO of Hallvarsson & Halvarsson, CFO of Synchron International and Vice President of Investor AB.

Shares: 10 000

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

**Hans GCP Schikan**

Born 1958. Pharm. D, Utrecht University. Board member since 2011. CEO of Prosensa, Holland. Executive board member of Top Institute Pharma and Member of Advisory Board BioScience Park Leiden. Previously Chairman of Dutch Association of the Innovative Pharmaceutical Industry, Nefarma. Various senior management positions within previous Organon and Genzyme.

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

**Hans Wigzell**

Born 1938. Med Dr. h.c., Professor Immunology. Board member since 2004. Chairman of Karolinska Development AB and Rhenman & Partners Asset Management AB. Board member of RaySearch Laboratories AB (publ), Intercell AG, HuMabs AG, AVI Biopharma and AB Wigzellproduktion. Member of the Royal Swedish Academy of Sciences and the Royal Swedish Academy of Engineering Sciences. Previously President of Karolinska Institutet and board member of NeoDynamics AB, PROBI AB and Diamyd Medical AB.

Shares: 200 000

Independent in relation to the company and its management and in relation to the company's principal shareholders.

***Proposal for election of new member of the board of directors::*****Matthew Gantz**

Born 1965. BA Princeton University and MBA from Harvard Business School. Regional US Executive Vice President and General Manager US in BTG, British Technology Group. Founder and previously CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc, VP Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe. Prior to Chiron/PathoGenesis a variety of US sales and marketing roles at Abbott Laboratories Diagnostics Division.

Shares: 0

He is independent in relation to the company and its management and in relation to the company's principal shareholders.